drugset / Trial / NCT03873883
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
Phase 1
Completed
119 enrolled
iTeos Therapeutics
Merck Sharp & Dohme LLC · collabiTeos Belgium SA · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 (Inupadenant) as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.
Timeline
- Start
- 2019-02-05
- Primary completion
- 2024-05-28
- Completion
- 2024-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | inupadenant | Small molecule | — | Oral |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |